PH
Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
$6.92 -2.26% (-$0.16)
1M -21.77%
Market Cap $572.8M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$9.86
42.5% upside
Current Price
$6.92
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PHAT is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
69 /100
Cheap P/S 2.39x
PEG N/A
P/E N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Op. margin 16.96%
Gross margin 82.92%
FCF margin 15.32%
Quality
13 /100
Poor Asset turnover 0.73x
ROIC 23.36%
ROA 30.29%
Debt
41 /100
Moderate Int. coverage -0.56x
Current ratio 1.92x
Debt/Assets N/A
Stability
49 /100
Moderate Profitable years 0
Beta 0.51x
EPS volatility 41.69%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PHAT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Steven L. Basta
Employees
371
Headquarters
Florham Park
Upcoming events
29 OCT
Earnings
Upcoming earnings report